合全藥業(yè)榮膺 “2023 CDMO 領(lǐng)軍企業(yè)獎(jiǎng)”-世界新消息

近日，藥明康德子公司合全藥業(yè)榮膺2023年“CDMO領(lǐng)軍企業(yè)獎(jiǎng)”，并獲得“能力”（Capabilities）以及 “可靠性”（Reliability）兩大核心獎(jiǎng)項(xiàng)。這也是合全藥業(yè)第九次榮膺“CDMO領(lǐng)軍企業(yè)獎(jiǎng)”。

【資料圖】

“CDMO Leadership Awards”由美國(guó)行業(yè)媒體Outsourced Pharma及Life Science Leader，與市場(chǎng)調(diào)研機(jī)構(gòu)Industry Standard Research（ISR）共同頒發(fā)，旨在表彰在“能力” (Capabilities)、“可靠性”（Reliability）等方面表現(xiàn)突出的全球優(yōu)質(zhì)合作研發(fā)生產(chǎn)企業(yè)。2023年，評(píng)審組邀請(qǐng)歐美大中小型公司圍繞23個(gè)關(guān)鍵指標(biāo)，對(duì)全球72家合同生產(chǎn)服務(wù)商進(jìn)行嚴(yán)格篩選與綜合評(píng)審，涵蓋全球范圍內(nèi)不同規(guī)模的制藥和生物制藥公司。合全藥業(yè)憑借卓越表現(xiàn)，再次脫穎而出榮膺獎(jiǎng)項(xiàng)，彰顯了全球合作伙伴對(duì)合全藥業(yè)一體化、端到端研發(fā)及生產(chǎn)服務(wù)能力的高度認(rèn)可。

合全藥業(yè)深耕CDMO領(lǐng)域20余年，目前在全球設(shè)有14個(gè)研發(fā)及生產(chǎn)基地，分別位于亞洲、北美及歐洲地區(qū)，全球員工已超過14,000名。僅2022年合全藥業(yè)就為全球1,200多家各類生物醫(yī)藥企業(yè)提供賦能服務(wù)。憑借業(yè)界領(lǐng)先的一體化CMC賦能平臺(tái)，以及符合國(guó)際標(biāo)準(zhǔn)的質(zhì)量體系，合全藥業(yè)2017年以來已成功支持合作伙伴的38款創(chuàng)新藥獲批，支持的新藥在全球105個(gè)國(guó)家上市。

藥明康德聯(lián)席首席執(zhí)行官、合全藥業(yè)首席執(zhí)行官陳民章博士表示：“我們很榮幸再次榮膺‘CDMO領(lǐng)軍企業(yè)獎(jiǎng)’，感謝合作伙伴對(duì)合全藥業(yè)的高度認(rèn)可及信任。合全藥業(yè)始終致力于為全球合作伙伴提供高質(zhì)量、可信賴、靈活的CRDMO服務(wù)，未來，我們將繼續(xù)提升平臺(tái)能力，助力加速創(chuàng)新藥開發(fā)進(jìn)程，為廣大病患帶來健康福音?！?/p>

關(guān)于合全藥業(yè)

合全藥業(yè)是藥明康德子公司，在亞洲、北美及歐洲地區(qū)均設(shè)有研發(fā)及生產(chǎn)基地。合全藥業(yè)服務(wù)于生命科學(xué)行業(yè)，擁有卓越的化學(xué)創(chuàng)新藥研發(fā)和生產(chǎn)的能力和技術(shù)平臺(tái)。作為全球新藥合同研究、開發(fā)與生產(chǎn)領(lǐng)域（CRDMO）的領(lǐng)軍企業(yè)，合全藥業(yè)致力于為全球合作伙伴提供高效、靈活、高質(zhì)量的一站式解決方案，以支持包括小分子、寡核苷酸、多肽及各種復(fù)雜化學(xué)偶聯(lián)藥物的研發(fā)與生產(chǎn)。更多信息，請(qǐng)?jiān)L問公司網(wǎng)站：www.stapharma.com.cn

WuXi STA Receives 2023 CDMO Leadership Award in Recognition of Capabilities and Reliabilities

WuXi STA, a global leading Contract Research, Development, and Manufacturing Organization (CRDMO), is pleased to share that it has been named a recipient of the 2023 CDMO Leadership Award for the ninth consecutive year. WuXi STA received recognition in two core categories: Capabilities and Reliabilities, which underscores the company’s ongoing commitment to supporting its global partners in new drug development.

For the 2023 CDMO Leadership Awards,?Outsourced Pharma?and?Life Science Leader?Magazine teamed up with Industry Standard Research (ISR) to conduct the Contract Manufacturing Quality Benchmarking survey that captured input from decision makers, aiming to recognize the top CDMOs achieving outstanding performance. 72 contract manufacturers were assessed by 23 performance metrics in ISR"s annual Contract Manufacturing Quality Benchmarking survey, covering all sizes of companies from both Pharma and Biopharma industries.

With over two decades of dedication to the CDMO industry, WuXi STA has established a global R&D and manufacturing network of 14 sites across North America, Asia, and Europe with over 14,000 employees, serving more than 1,200 customers in 2022 alone. By leveraging its end-to-end integrated CRDMO platform and a global standard quality system, WuXi STA has supported the approval of 38 new drugs since 2017. The products manufactured by the company have been launched in 105 countries, helping millions of patients worldwide.

Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, commented, “We are honored to receive the 2023 CDMO Leadership Award again this year, and we are grateful to our partners for their recognition and trust. WuXi STA remains committed to delivering world-class CRDMO services to accelerate life-changing medicines to market for the benefit of patients around the world.”

About WuXi STA

WuXi STA (stapharma.com), a subsidiary of WuXi AppTec (wuxiapptec.com), is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier contract development and manufacturing organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate.?

For more information, please visit:?http://www.STApharma.com

關(guān)鍵詞： 合全藥業(yè)榮膺 2023 CDMO 領(lǐng)軍企業(yè)獎(jiǎng) 藥明康德